Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: A round table discussion

Thorax

Volumn 69, Issue 12, 2014, Pages 1136-1140

  Thickett, David R ^a   Kendall, Clare ^b   Spencer, Lisa G ^c   Screaton, Nick ^d   Wallace, William A ^e   Pinnock, Hilary ^f   Bott, Julia ^g   Pigram, Lucy ^h   Watson, Sarah ⁱ   Millar, Ann B ^j  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NORTH BRISTOL NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d PAPWORTH HOSPITAL   (United Kingdom)

^e Department of Pathology ^*  (United Kingdom)

^f General Practice   (United Kingdom)

^g Respiratory Care Team Surrey PCT   (United Kingdom)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ NATIONAL HEALTH SERVICE   (United Kingdom)

^j UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PROTEIN TYROSINE KINASE INHIBITOR;

CLINICAL NURSE SPECIALIST; CLINICAL PATHWAY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EARLY DIAGNOSIS; FIBROSING ALVEOLITIS; HEALTH CARE ACCESS; HEALTH SERVICE; HUMAN; INCIDENCE; LONG TERM CARE; MEDICAL EDUCATION; NURSE ATTITUDE; OCCUPATIONAL THERAPY; OPEN LUNG BIOPSY; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PULMONARY REHABILITATION; QUALITY OF LIFE; RADIOLOGY; RARE DISEASE; REVIEW; SPIROMETRY; SURVIVAL RATE; SYMPTOM; THORAX RADIOGRAPHY; UNITED KINGDOM; ARTIFICIAL VENTILATION; CONSENSUS DEVELOPMENT; HEALTH CARE DELIVERY; IDIOPATHIC PULMONARY FIBROSIS; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROCEDURES; STANDARDS; TOTAL QUALITY MANAGEMENT;

DELIVERY OF HEALTH CARE; EARLY DIAGNOSIS; GREAT BRITAIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PALLIATIVE CARE; PRIMARY HEALTH CARE; QUALITY IMPROVEMENT; RESPIRATORY THERAPY;

EID: 84919783095     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206284     Document Type: Review

References (27)

1. NICE. The diagnosis and management of suspected idiopathic pulmonary fibrosis. NICE clinical guideline 163, 2013.
2. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-61.
3. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66:462-7.
4. Cottin V, Richeldi L. Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. Eur Respir Rev 2014;23:106-10.
5. Okkes IM, Oskam SK, Lamberts H. The probability of specific diagnoses for patients presenting with common symptoms to Dutch family physicians. J Fam Pract 2002;51:31-6.
6. IMPRESS. Breathlessness IMPRESS Tips. http://www.networks.nhs.uk/nhs-networks/impress-improving-and-integrating-respiratory
7. Levy ML, Quanjer PH, Booker R, et al. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG)1 document, in association with the Association for Respiratory Technology & Physiology (ARTP)2 and Education for Health3 1 http://www.gpiag.org2 http://www.artp.org 3 http://www.educationforhealth.org.uk. Prim Care Respir J 2009;18:130-47.
8. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
9. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
10. Lettieri CJ, Veerappan GR, Parker JM, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med 2005;99:1425-30.
11. Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-5.
12. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur Respir J 2011;37:743-6.
13. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
14. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-14.
15. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl 5):v1-58.
16. Bott J, Blumenthal S, Buxton M, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009;64(Suppl 1):i1-51.
17. Nishiyama O, Miyajima H, Fukai Y, et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med 2013;107:1241-6.
18. Egan JJ. Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient. Eur Respir Rev 2011;20:114-17.
19. Foundation. BL. IPF Patient Charter.
20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
21. Parker S, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manage 2007;34:81-93.
22. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fi brosis. N Engl J Med 2014;370:2083-92.
23. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000prime Rep 2014;6:16.
24. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
25. Kuwano K. Involvement of epithelial cell apoptosis in interstitial lung diseases. Intern Med 2008;47:345-53.
26. Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax 2014;69:760-5.
27. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011;38:1461-7.